Why the study?
Depression is a prevalent comorbidity in CHD, but existing evidence regarding the association between CHD and antidepressants such as sertraline remains inconclusive.
Do serotonin-targeting antidepressants like sertraline improve mood status and reduce cardiovascular events in depressed patients with or at risk for coronary heart disease?
Do serotonin-targeting antidepressants like sertraline improve mood status and reduce cardiovascular events in depressed patients with or at risk for coronary heart disease?
Serotonin-targeting antidepressants like sertraline appear to safely improve depressive symptoms and may reduce the risk of adverse coronary outcomes in patients with or at risk for cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Supports integrating serotonin-targeting antidepressants into care for depressed cardiac patients; extends aggregated evidence on efficacy and safety.
BACKGROUND AND AIMS: Depression is a prevalent comorbidity among patients with coronary heart disease (CHD). While recent studies have hinted at a possible association between CHD and antidepressant medications like sertraline, the existing evidence remains inconclusive. To investigate this potential link, we conducted a comprehensive systematic review. METHODS: We systematically searched PubMed, Google Scholar, and Scopus for relevant articles published up to March 2023. After a thorough screening of titles and abstracts, 12 studies were included in our review. RESULTS: The included studies, spanning from 1999 to 2021, comprised 11 randomized controlled trials (RCTs) and one pilot study. A total of 2767 participants with major depressive disorder and a history of cardiovascular disease or at risk for such events were included. The majority of these studies demonstrated improvements in mood status among patients treated with serotonin-targeting antidepressants and a reduced risk of cardiovascular events, as measured by various outcomes. While some cardiac adverse effects were observed with serotonin treatment, these did not reach statistical significance. CONCLUSION: Our findings provide evidence supporting the beneficial effects of serotonin-targeting antidepressants for both depressive symptoms and the prevention of coronary adverse outcomes. These results highlight the potential value of serotonin-based treatments for depression in high-risk populations.
No takes yet. Share an insight, caveat, or question.
Kiana Seifouri (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: